Bonifacio, L.; Ramacciotti, E.; Agati, L.; Vilar, F.; Tojal, A.; Souza, H.; Louzada Júnior, Paulo; Fonseca, Benedito Antonio Lopes da; Lopes, R.; Kallas, Esper Georges 
; Bellíssimo-Rodrigues, Fernando
Source: Antimicrobial Resistance & Infection Control. Conference titles: International Conference on Prevention & Infection Control (ICPIC 2021). Unidades: FMRP, FM
Subjects: COVID-19, PACIENTES INTERNADOS, ESTUDOS MULTICÊNTRICOS, ESTUDOS PROSPECTIVOS, CITOCINAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONIFACIO, L. et al. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf. Acesso em: 08 nov. 2025. , 2021APA
Bonifacio, L., Ramacciotti, E., Agati, L., Vilar, F., Tojal, A., Souza, H., et al. (2021). Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Recuperado de https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdfNLM
Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2025 nov. 08 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdfVancouver
Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2025 nov. 08 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf
